Company intelligence / Profile preview
Tetra Therapeutics
Grand Rapids, Michigan, United Statestetratherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 2 clinical trials for Fragile X syndrome and early Alzheimer's disease. Results from Alzheimer's study showed evidence for slowing disease progression. Phase 3 clinical trials are underway for Fragile X syndrome in males with results expected in the second half of 2024.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Shionogi & Co., Ltd. (acquired by)
Beyond the preview
Go deeper on Tetra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetra Therapeutics.